New results from an Irish observational study demonstrate the efficacy of Rasilez in reducing blood pressure in a real life setting PDF (643KB) Novartis wish to announce the results of DRIve (Ireland), an Irish observational study designed to assess the efficacy, safety and tolerability of Rasilez (aliskiren) in a real life setting.1 Ten thousand people [...]
In the case of urgent and/or important safety issues about a medicinal product, a Direct Healthcare Professional Communication (DHPC) is used to notify healthcare professionals. A DHPC (also known as a ‘Dear Doctor Letter’) aims to ensure safe and effective use of a marketed medicine and is delivered directly to healthcare professionals by marketing authorisation [...]
Fluoroquinolones are broad spectrum antibiotics, authorised for a wide range of indications. Those currently authorised in Ireland include: moxifloxacin, levofloxacin, ofloxacin and ciprofloxacin*. The potential for fluoroquinolones to cause QT prolongation is recognised and has been previously considered on the basis of available data for the individual substances, as reflected in the product specific information. [...]
The incidence of Staphylococcus aureus bacteraemia (SAB) has increased significantly during the past few decades and S. aureus has become a leading cause of bloodstream infections in most of the industrialized world. MRSA Facts1 Carriage of S. aureus with colonisation of skin and mucosa is common and often harmless, but may evolve into a wide [...]
Electron micrograph (SEM) of methicillin-resistant Staphylococcus aureus bacteria (MRSA); Magnification 2363x. Infective Endocarditis1 The prevalence of cardiac device infections in patients with S. aureus bacteremia (SAB) is approximately 50%. The prevalence of infective endocarditis in SAB patients ranges from 11 to 50%. The number of cardiac devices implanted has increased dramatically together with [...]
There are many antibiotics that are used to treat MRSA infection, including those with specific licenses for MRSA and other older drugs, which may not have a specific license but which are widely regarded as effective. Table 1: Antibiotics available for treatment of MRSA infections1 Agent Drug class Indications Route of administration Vancomycin Glycopeptide Standard treatment [...]
The wide spectrum of illness caused by MRSA includes skin and soft tissue infections, bacteremia and endocarditis, pneumonia, bone and joint infections, UTI and CNS disease. Table: Guidelines for the treatment of MRSA1,2 – Step-down therapy from agent encompassing MRSA to flucloxacillin, unless known very low MRSA rates. – As a general rule, use glycopeptides [...]
Company: Actavis Ireland Ltd. Legal category: Prescription. GMS. Sport prohibited. Active ingredient: Anastrozole 1mg. Description: White, round, biconvex film-coated tablets marked ANA and 1 on one side. Presentation: 28, €67.27. Indication: Treatment of advanced breast cancer in postmenopausal women. Pharmacology: Anastrozole is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is [...]
Company: Niche Generics Ltd. Legal category: Prescription. GMS. Sport prohibited. Active ingredient: Anastrozole 1mg. Description: White, round, biconvex, film-coated tablets marked 1 on one side. Presentation: 28, €64.14. Indication: Treatment of advanced breast cancer in postmenopausal women. Pharmacology: Anastrozole is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is produced primarily [...]
Company: Genzyme Therapeutics Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Colesevelam (as hydrochloride) 625mg. Description: Off-white, capsule-shaped film-coated tablets imprinted with Cholestagel on one side. Presentation: 180, €124.87. Indications: In combination with a statin as adjunct to diet to provide an additive reduction in low-density lipoprotein cholesterol (LDL-C) levels in adults with primary [...]
Loading ...
